We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma.
- Authors
Sun, Zhenchang; Wan, Wenjuan; Zhang, Xudong; Zhang, Lei; Li, Xin; Li, Ling; Wang, Xinhua; Nan, Feifei; Yu, Hui; Chang, Yu; Yan, Jiaqin; Li, Zhaoming; Cui, Fangfang; Ge, Jurui; XiaXu, Yaqin Duo; Xu, Xia; Fu, Xiaorui; Zhang, Mingzhi
- Abstract
Purpose: To investigate the clinical characteristics and prognostic factors of natural killer/T-cell lymphoma (NKTCL). Methods: We retrospectively reviewed 410 NKTCL patients admitted to our lymphoma center from 2000 to 2019. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method, and the differences between the study groups were compared by the log-rank test. Results: The median age of the 410 patients was 44 (range 8–84), and the 5-year OS and PFS were 61.2% and 38.4%, respectively. For patients with stage I/II, the 5-year PFS rate was 57.5%, and the 5-year OS rate was 77.2%. For patients with stage III/IV, the 5-year PFS rate was 17.4%, and the 5-year OS rate was 43.7%. Compared to the patients who received radiotherapy alone or chemotherapy alone as their initial treatment, the patients who received combined chemoradiotherapy had longer PFS (P = 0.013). Independent prognostic factors for OS were stage III/IV (P = 0.001), elevated IPI/aaIPI score (P = 0.019), elevated PINK score (P < 0.001) and elevated plasma EBV-DNA (P = 0.003). An elevated PINK score (P < 0.001) was an independent prognostic factor for PFS. Conclusion: Stage III/IV, elevated IPI/aaIPI score, elevated PINK score and elevated plasma EBV-DNA were independent prognostic factors for OS. Elevated PINK score was an independent prognostic factor for PFS. In stage III/IV patients, the patients who received combined chemoradiotherapy had significantly longer PFS.
- Subjects
PROGNOSIS; OVERALL survival; PROGRESSION-free survival; LYMPHOMAS; LOG-rank test
- Publication
Journal of Cancer Research & Clinical Oncology, 2022, Vol 148, Issue 12, p3449
- ISSN
0171-5216
- Publication type
Article
- DOI
10.1007/s00432-022-04203-x